Literature DB >> 33489486

Primary Central Nervous System Lymphoma Presenting as Multifocal Brain Abscesses.

Sai Liang1, Jia Xu Lim1, Hwei Yee Lee2, Sharon Yy Low1.   

Abstract

A previously well female presented with a history of progressive functional decline. She had a known history of generalized seropositive myasthenia gravis on long-term mycophenolate mofetil and pyridostigmine. MRI of her brain reported multiple cerebral abscesses based on radiological features. The patient was commenced on intravenous antibiotics, but there was no clinical or radiological response to treatment. Decision was made for a stereotactic biopsy. Intraoperative tissue cultures were negative for infection. However, histology reported B-cell lymphoma with morphological features changes typically seen in corticosteroid-treated lymphoma - an unexpected finding as no steroids were administered as part of her treatment. Owing to the unusual diagnosis, the case is presented in corroboration with current literature.
Copyright © 2020, Liang et al.

Entities:  

Keywords:  brain abscess; central nervous system lymphoma; immunosuppressant

Year:  2020        PMID: 33489486      PMCID: PMC7805420          DOI: 10.7759/cureus.12068

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

1.  Primary intracerebral malignant lymphoma: report of 248 cases.

Authors:  B Bataille; V Delwail; E Menet; P Vandermarcq; P Ingrand; M Wager; G Guy; F Lapierre
Journal:  J Neurosurg       Date:  2000-02       Impact factor: 5.115

Review 2.  MRI in central nervous system infections: A simplified patterned approach.

Authors:  Krithika Rangarajan; Chandan J Das; Atin Kumar; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2014-09-28

Review 3.  Mechanisms of action of mycophenolate mofetil.

Authors:  A C Allison
Journal:  Lupus       Date:  2005       Impact factor: 2.911

4.  Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings.

Authors:  M M Thurnher; A Rieger; C Kleibl-Popov; U Settinek; C Henk; C Haberler; E Schindler
Journal:  Neuroradiology       Date:  2001-01       Impact factor: 2.804

Review 5.  Magnetic resonance features of primary central nervous system lymphoma in the immunocompetent patient: a pictorial essay.

Authors:  Kelvin K Yap; Tom Sutherland; Elaine Liew; Con J Tartaglia; Mei Pang; Nick Trost
Journal:  J Med Imaging Radiat Oncol       Date:  2012-03-06       Impact factor: 1.735

Review 6.  Primary central nervous system lymphoma in immunocompetent patients: a retrospective review of MRI features.

Authors:  Tom Sutherland; Kelvin Yap; Elaine Liew; Con Tartaglia; Mai Pang; Nicholas Trost
Journal:  J Med Imaging Radiat Oncol       Date:  2012-04-10       Impact factor: 1.735

Review 7.  Primary central nervous system lymphoma.

Authors:  H A Fine; R J Mayer
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

8.  Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability.

Authors:  Evrim Önder; Ata T Arıkök; Sevgen Önder; Ünsal Han; Mehmet Sorar; Hayri Kertmen; Engin D Yılmaz; Ramazan Fesli; Murat Alper
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 9.  Primary central nervous system lymphoma.

Authors:  Sharathkumar Bhagavathi; Jon D Wilson
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

10.  AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989-2003.

Authors:  Ingfrid S Haldorsen; Jostein Kråkenes; Anne K Goplen; Oona Dunlop; Olav Mella; Ansgar Espeland
Journal:  BMC Cancer       Date:  2008-08-06       Impact factor: 4.430

View more
  1 in total

1.  A steady stream of knowledge: decreased urinary retention after implementation of ERAS protocols in ambulatory minimally invasive inguinal hernia repair.

Authors:  Ryan C Broderick; Jonathan Z Li; Rachel R Blitzer; Pranav Ahuja; Alice Race; Gene Yang; Bryan J Sandler; Santiago Horgan; Garth R Jacobsen
Journal:  Surg Endosc       Date:  2022-01-04       Impact factor: 3.453

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.